RET and lung carcinoma: While molecular testing of the more common targetable alterations, including EGFR mutations and ALK fusions, in advanced NSCLC is recommended by national and international lung cancer guidelines, testing for RET fusions has not yet been as widely adopted, at least partly owing to the dearth of selective RET inhibitors until recently [41,42].